Skip to content

Ketamine research published in 2024

Page 12 of 26: studies 221 to 240 of 518, newest first. Back to the ketamine overview

Studies

Evaluation of the Use of Ketamine in Prehospital Seizure Management: A Retrospective Review of the ESO Database.

Prehospital emergency care July 31, 2024 Joseph Daniel Finney, Paul D Schuler, James R Rudloff et al. 4 citations

Benzodiazepines are the primary antiseizure medication used by Emergency Medical Services (EMS) for seizures. Available literature in the United States and internationally shows 30% to 40% of seizures do not terminate with benzodiazepines called benzodiazepine refractory status epilepticus (BRSE). Ketamine is a potential treatment for BRSE due to its unique pharmacology. However, its...

DOI: 10.1080/10903127.2024.2382367 (opens in new tab) Full text (opens in new tab) Seizure treatment Ketamine therapy Emergency medicine Drug-resistant epilepsy +1

The N-methyl-d-aspartate receptor hypothesis of ketamine's antidepressant action: evidence and controversies.

Philosophical transactions of the Royal Society of London. Series B, Biological sciences July 29, 2024 Yihao Jiang, Yiyan Dong, Hailan Hu

Substantial clinical evidence has unravelled the superior antidepressant efficacy of ketamine: in comparison to traditional antidepressants targeting the monoamine systems, ketamine, as an N-methyl-d-aspartate receptor (NMDAR) antagonist, acts much faster and more potently. Surrounding the antidepressant mechanisms of ketamine, there is ample evidence supporting an NMDAR-antagonism-based...

DOI: 10.1098/rstb.2023.0225 (opens in new tab) Full text (opens in new tab) Nmdar hypothesis Nmdar inhibitors Antidepressant efficacy Depression treatment +4

Ketamine in fibromyalgia: a systematic review.

Advances in rheumatology (London, England) July 29, 2024 Jozélio Freire de Carvalho, Eduardo Pondé de Sena 8 citations

Fibromyalgia (FM) subjects are treated with antidepressant agents; in most cases, these drugs lose efficacy or have adverse effects. Ketamine is an anesthetic drug used in FM in some studies. This article aims to systematically review the safety and efficacy of ketamine in fibromyalgia (FM) patients. We systematically searched articles on FM and ketamine published at Pubmed from 1966 to 2021....

DOI: 10.1186/s42358-024-00393-9 (opens in new tab) Full text (opens in new tab) Depression Anesthetics Ketamine therapy Chronic pain treatment +3

Basic aspects of ketamine therapy for treatment-resistant depression - a review paper

Quality in Sport July 28, 2024 Weronika Szafrańska, Dominika Poborowska, Tomasz Gańko et al.

Introduction and purpose: Major depressive disorder (MDD) is the most common psychiatric illness, affecting millions of people worldwide. The first line of pharmacological treatment is usually monoamine reuptake inhibitors. Up to 60% of cases, may be drug-resistant patients, prompting researchers to research substances other than conventional. 1 The purpose of this article was to review recent...

High-order brain interactions in ketamine during rest and task: a double-blinded cross-over design using portable EEG on male participants.

Translational Psychiatry July 27, 2024 Rubén Herzog, Florentine Marie Barbey, Md Nurul Islam et al. 13 citations

Ketamine is a dissociative anesthetic that induces a shift in global consciousness states and related brain dynamics. Portable low-density EEG systems could be used to monitor these effects. However, previous evidence is almost null and lacks adequate methods to address global dynamics with a small number of electrodes. This study delves into brain high-order interactions (HOI) to explore the...

mTORC1 activation in presumed classical monocytes: observed correlation with human size variation and neuropsychiatric disease.

Aging July 26, 2024 Karl Berner, Naci Oz, Alaattin Kaya et al. 1 citation

Gain of function disturbances in nutrient sensing are likely the largest component in human age-related disease. Mammalian target of rapamycin complex 1 (mTORC1) activity affects health span and longevity. The drugs ketamine and rapamycin are effective against chronic pain and depression, and both affect mTORC1 activity. Our objective was to measure phosphorylated p70S6K, a marker for mTORC1...

Transient peripheral blood transcriptomic response to ketamine treatment in children with ADNP syndrome.

Translational Psychiatry July 25, 2024 Ariela S. Buxbaum Grice, Laura G Sloofman, Tess Levy et al. 3 citations

Activity-dependent neuroprotective protein (ADNP) syndrome is a rare neurodevelopmental disorder resulting in intellectual disability, developmental delay and autism spectrum disorder (ASD) and is due to mutations in the ADNP gene. Ketamine treatment has emerged as a promising therapeutic option for ADNP syndrome, showing safety and apparent behavioral improvements in a first open label study....

Hippocampal PACAP signaling activation triggers a rapid antidepressant response.

Military Medical Research July 23, 2024 Hai-Lou Zhang, Yan Sun, Zhang-Jie Wu et al. 24 citations

The development of ketamine-like rapid antidepressants holds promise for enhancing the therapeutic efficacy of depression, but the underlying cellular and molecular mechanisms remain unclear. Implicated in depression regulation, the neuropeptide pituitary adenylate cyclase-activating polypeptide (PACAP) is investigated here to examine its role in mediating the rapid antidepressant response. The...

DOI: 10.1186/s40779-024-00548-1 (opens in new tab) Full text (opens in new tab) Ketamine Antidepressant response Optogenetic Depression treatment +3

A randomized controlled pilot study of daily intravenous ketamine over three days for treatment-resistant depression.

BMC Psychiatry July 18, 2024 Keerati Pattanaseri, Juthawadee Lortrakul, Kankamol Jaisin et al. 11 citations

Studies have confirmed the rapid antidepressant action of ketamine in depressive episodes. Nevertheless, a standardized procedure for the delivery of ketamine infusion in individuals suffering from treatment-resistant depression, particularly in terms of infusion frequency and total dosage, remains undetermined. In addition, an efficacious ketamine regimen for persistent pain management...

DOI: 10.1186/s12888-024-05951-5 (opens in new tab) Full text (opens in new tab) Response Tolerability Depression treatment Ketamine therapy +3

Effect of ketamine enantiomers and maternal deprivation on depressive-like behavior and plasma concentration of BDNF in rats

Research, Society and Development July 15, 2024 G. Beanes, Beatriz A Carneiro, G. Marques et al.

Background: Low doses of different ketamine enantiomers have demonstrated rapid behavioural and biological actions in animals with depressive-like behavior. However, some authors report different effects depending on model of depression and ketamine isomer used. Objective: Our primary aim was to evaluate the effect of ketamine enantiomers on depressive-like behavior, anhedonic-like behavior and...

Long-term follow-up of participants in ketamine clinical trials for mood disorders.

Journal of Affective Disorders July 15, 2024 Kelly T Hurst, Abigail Vogeley, Deanna K Greenstein et al. 8 citations

Participants who received ketamine at the NIMH were among the first to receive ketamine for depression in controlled clinical trials, providing a unique opportunity to assess long-term outcomes. This analysis evaluated the relationship between participating in a ketamine clinical trial and subsequent ketamine/esketamine use after leaving the research setting. Participants seen within the NIMH...

DOI: 10.1016/j.jad.2024.04.062 (opens in new tab) Full text (opens in new tab) Esketamine Clinical trials Clinical-trials Depression-treatment +3

Esketamine in depression: putative biomarkers from clinical research.

European Archives of Psychiatry and Clinical Neuroscience July 13, 2024 Jenessa N Johnston, Carlos A. Zarate, Mark D Kvarta 18 citations

The discovery of racemic (R, S)-ketamine as a rapid-acting antidepressant and the subsequent FDA approval of its (S)-enantiomer, esketamine, for treatment-resistant depression (TRD) are significant advances in the development of novel neuropsychiatric therapeutics. Esketamine is now recognized as a powerful tool for addressing persistent symptoms of TRD compared to traditional oral...

DOI: 10.1007/s00406-024-01865-1 (opens in new tab) Full text (opens in new tab) Spravato Mechanism of action Suicide Treatment-resistant depression trd +6

Nitric Oxide Donor Sodium Nitroprusside Reduces Racemic Ketamine-But Not Esketamine-Induced Pain Relief.

ACS Pharmacology & Translational Science July 12, 2024 Albert Dahan, Simone C Jansen, Rutger van der Schrier et al. 8 citations

The anesthetic, analgesic and antidepressant drug ketamine produces dissociation with symptoms of psychosis and anxiety, an effect attributed to neuronal nitric oxide depletion following N-methyl-d-aspartate blockade. There is evidence that dissociation induced by racemic ketamine, containing both ketamine enantiomers (S- and R-ketamine) but not esketamine (the S-isomer) is inhibited by nitric...

DOI: 10.1021/acsptsci.4c00133 (opens in new tab) Full text (opens in new tab) Ketamine research Pain medication Blood pressure drugs Pharmacology +1

Electroencephalography and Magnetoencephalography Signatures of Ketamine Treatment in Depression: A Literature Review

Undergraduate Research in Natural and Clinical Science and Technology (URNCST) Journal July 11, 2024 Eva M. Geoghegan

Introduction: Ketamine has been shown to have rapid antidepressant effects. In addition, the use of EEG in depression offers a new approach to diagnose patients. It is necessary to understand locational-based EEG and MEG changes following ketamine in patients with depression to establish a potential biomarker panel. This study sought to identify consistent changes in band power as well as to...

Ketamine and its two enantiomers in anesthesiology and psychiatry: A historical review and future directions

Journal of Anesthesia and Translational Medicine July 11, 2024 Kenji Hashimoto, Mingming Zhao, Tingting Zhu et al. 32 citations

Ketamine, a dissociative anesthetic, is widely utilized in both human and veterinary anesthesia. Its (S)-enantiomer, esketamine, is similarly employed for anesthesia and analgesia. The anesthetic effects of both ketamine and esketamine arise from their antagonism of the N-methyl-D-aspartate receptor (NMDAR). In field of psychiatry, the rapid-acting antidepressant properties of ketamine for...

The effectiveness of ketamine in medication of treatment-resistant depression - review

Quality in Sport July 10, 2024 Patrycja Brzozowska, Klaudia Bulska, Konrad Sławek et al.

In spite of the variety of antidepressant drugs available for treating depressive disorder, treatment resistant depression (TRD) is still prevalent among the population. Despite being used mainly in anesthesia, and mostly phased out by more modern anesthetics, ketamine shows potential when it comes to depressive disorder treatment. We've set out to investigate the the relevant body of work to...

Effects of Low-Dose Ketamine Infusion on the Positive and Negative Domains of Hopelessness and Suicidal Thoughts.

The Journal of Clinical Psychiatry July 8, 2024 Wei-Chen Lin, Mu-Hong Chen, Tung-Ping Su et al. 4 citations

Background: Low-dose ketamine infusion has been demonstrated to exert antisuicidal effects on patients with treatment-resistant depression (TRD) and strong suicidal ideation. Although evidence suggests an association between hopelessness and suicidality, very few studies have investigated the antihopelessness effects of ketamine. Methods: This study included 84 patients with TRD and strong...

DOI: 10.4088/JCP.24m15257 (opens in new tab) Full text (opens in new tab) Mental health Ketamine therapy Suicide prevention Depression treatment +1

Intravenous ketamine for emergency department treatment of suicidal ideation in a paediatric population: protocol for a double-blind, randomised, placebo-controlled, parallel-arm pilot trial (KSI study).

BMJ Open July 5, 2024 Michael Schlegelmilch, Amy C. Plint, Nicholas Barrowman et al. 2 citations

Suicidal ideation (SI) is a common and severe cause of morbidity in adolescents. Patients frequently present to the emergency department (ED) for care, yet there is no acute therapeutic intervention for SI. A single dose of intravenous ketamine has demonstrated efficacy in rapidly reducing SI in adults; however, ketamine has not been studied in paediatrics. We aim to determine the feasibility...

DOI: 10.1136/bmjopen-2024-085681 (opens in new tab) Full text (opens in new tab) Emergency service, hospital Paediatrics Suicide & self-harm Pediatric mental health +4

A Comparative Study on the Effectiveness of Electroconvulsive Therapy and Ketamine in Persons Suffering from Treatment-resistant Depressive Disorder

Indian Journal of Psychiatric Nursing July 1, 2024 V. Ramasubramanian, S. Mathumathi, G. Thirumalaisamy et al.

ABSTRACT Depression is a common illness that affects about 3.8% of the population worldwide. Patients with major depression respond to antidepressant treatment, but 10%–20% of them do not improve or show a partial response. It is coupled with functional impairment, poor quality of life, suicide ideation and attempts, self-injurious behavior, and a high relapse rate. Treatment-resistant...

The role of mGluR5 on the therapeutic effects of ketamine in Wistar rats.

Psychopharmacology July 1, 2024 Dilan Gokalp, Gunes Unal

Ketamine produces dissociative, psychomimetic, anxiolytic, antidepressant, and anesthetic effects in a dose dependent manner. It has a complex mechanism of action that involve alterations in other glutamate receptors. The metabotropic glutamate receptor 5 (mGluR5) has been investigated in relation to the psychotic and anesthetic properties of ketamine, while its role in mediating the...